Selexis and Generium launched an omalizumab biosimilar on the Russian market; Remsima sales hit a record high for Celltrion Healthcare; Xbrane Biopharma shares long-term results for its ranibizumab biosimilar.
Selexis and Generium shared that they have launched Genolar, a biosimilar for omalizumab (Xolair) on the Russian market for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria for patients aged 6 years and up.
“Individuals coping with chronic diseases such as atopic asthma deserve access to novel, affordable medicines. The introduction of effective biosimilars like Genolar makes that possible, while also aligning with Selexis’ patient-centric mission,” said Roland Hecht, PhD, chief business officer at Selexis.
The drug is the first Selexis SUREtechnology Platform-generated biosimilar to reach that market under a commercialization partnership with Generium. The biosimilar is also cleared for use in patients with chronic spontaneous urticaria in patients aged 12 years and older with elevated immunoglobulin E (IgE) who are unresponsive to antihistamine treatment. Omalizumab is a recombinant humanized monoclonal antibody that bind to free human IgE.
According to Yonhap News Agency, sales of Celltrion Healthcare’s infliximab biosimilar Remsima reached a new record in 2021 in the United States, jumping up 13% in year-over-year growth to $385 million.
Remsima references Remicade and has been on the US market since November 2016, when it launched under the name Inflectra as part of a commercialization partnership between Celltrion and Pfizer. Remsima is used to treat patients with rheumatoid arthritis and several other rheumatologic conditions.
At the end of 2021, the market share for the biosimilar amounted to 22.3% in the United States, which is lower than Remicade’s 67.2% market share but it is still gaining traction. Over the last 5 years, sales of the reference product had been cut by nearly half, from $4.5 billion in 2017 to $2 billion in 2021, following the launch of Celltrion’s product.
The news of the record breaking growth comes around the same time as Hikma Pharmaceuticals announced the expansion in its licensing agreement with Celltrion over the subcutaneous version of Remsima for their Middle Eastern and North African (MENA) markets. The expansion builds on the companies’ existing partnership for 3 biosimilar products, including Truxima (rituximab), the original Remsima formulation, and Herzuma (trastuzumab).
“Subcutaneous administration has been shown to be effective, safe, well-tolerated and generally preferred by patients. This new formulation enables administration outside of the hospital setting, allowing more patients access to the treatment,” said Mazen Darwazah, the executive vice chairman of Hikma and president of MENA.
Hikma’s MENA markets include those in Algeria, Egypt, Iraq, Jordan, Morocco, Tunisia, the United Arab Emirates, and Saudi Arabia.
Xbrane Biopharma announced positive phase 3 trial results demonstrating equivalent efficacy for its ranibizumab biosimilar Xlucane in comparison with the reference product (Lucentis) over 12 months.
The company said that the results will help the company along its journey for regulatory approval for various markets. Ranibizumab is a blood vessel growth inhibitor used to treat neovascular age-related macular degeneration (wet AMD), macular edema, and diabetic retinopathy.
The company said that the Xplore study results revealed no clinically meaningful differences in safety, efficacy, pharmacokinetics, or immunogenicity between the 2 drugs. The Xplore study is a randomized, double-blinded, multi-center study comparing the safety and efficacy properties of Xlucane compared with the reference product in patients with wet AMD. The study pulls data from 583 patients from 140 clinics in 15 countries.
Previous data shared from the trial demonstrated equivalent efficacy in the change of best corrected visual acuity after 8 weeks of treatment compared to the reference product.
Resolution of Injection Site Reactions After Switching to Adalimumab Biosimilar
February 22nd 2025A 15-year-old girl with ulcerative colitis who developed injection site reactions to the adalimumab reference product was successfully switched to the biosimilar LBAL without recurrence of symptoms, demonstrating the safety and effectiveness of switching for medical reasons, likely due to an allergic reaction to an excipient in the originator.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
FDA, EMA Approve Second Pair of Denosumab Biosimilars
February 17th 2025The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' denosumab biosimilars, which will be marketed under different names depending on whether they will be used to treat osteoporosis or bone metastases.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.